Omniscan (Gadodiamide)

Omniscan is a gadolinium‑based contrast agent used in magnetic resonance imaging to improve diagnostic clarity across several clinical scenarios.

• Central nervous system imaging: Improves lesion detection and delineation in brain and spinal cord studies.
• Vascular imaging: Enhances visualization of arteries, veins and aneurysms.
• Whole‑body and oncologic imaging: Improves detection of metastatic disease and tumor margins.
• Cardiac MRI: Provides clearer definition of myocardial perfusion and scar tissue.
• Pediatric MRI: Facilitates better contrast in children’s neuro‑vascular studies.

• Gadodiamide is a low‑osmolar, non‑ionic gadolinium chelate that distributes in the extracellular fluid after intravenous injection. Its paramagnetic gadolinium ion shortens the T1 relaxation time of nearby water protons, producing a brighter signal on T1‑weighted MRI sequences and thereby enhancing the contrast between normal and pathological tissues.

Adverse reactions to Omniscan are generally uncommon but can range from mild to severe.

Common Side Effects

• Nausea: Mild, transient feeling of stomach upset.
• Headache: Temporary headache occurring shortly after injection.
• Injection site discomfort: Minor pain or burning at the site of administration.
• Warmth sensation: Brief feeling of warmth or flushing.
• Dizziness: Light‑headedness that resolves quickly.

Serious or Rare Side Effects

• Nephrogenic systemic fibrosis (NSF): A rare fibrotic disorder in patients with severe renal impairment.
• Severe allergic reaction: Anaphylaxis or anaphylactoid responses requiring immediate medical attention.
• Cardiac arrest: Extremely rare but potentially life‑threatening event.
• Pulmonary edema: Accumulation of fluid in the lungs, observed in isolated cases.
• Acute kidney injury: Deterioration of renal function following exposure.

When using Omniscan, clinicians should assess patient history and monitor for specific risks.

• Renal function assessment: Evaluate glomerular filtration rate before administration.
• History of allergic reactions: Review prior contrast media reactions.
• Pregnancy considerations: Use only if clearly needed, weighing fetal risk.
• Pediatric dosing: Adjust volume based on weight and clinical protocol.
• Concomitant nephrotoxic drugs: Avoid or monitor use of other renal‑impacting agents.
• Store at 2‑8°C: Keep refrigerated, protect from light, do not freeze or shake.

Omniscan may interact with other agents that affect renal function or hypersensitivity risk.

Major Interactions (Avoid)

• Loop diuretics: May exacerbate renal impairment when combined with gadolinium agents.
• High‑dose intravenous iron: Can increase the risk of free gadolinium release.

Moderate Interactions (Monitor Closely)

• Non‑steroidal anti‑inflammatory drugs (NSAIDs): May compound renal stress.
• Metformin: Requires temporary discontinuation in patients with reduced kidney function.
• ACE inhibitors/ARBs: May affect renal haemodynamics, necessitating close monitoring.
• Radiopharmaceuticals: Concurrent use may alter imaging interpretation.